Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW870086 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GW870086 2mg | EXPERIMENTAL | GW870086 2mg once daily in the morning for 27 ± 2 days |
| GW870086 4mg | EXPERIMENTAL | GW870086 4mg once daily in the morning for 27 ± 2 days |
| Placebo | PLACEBO_COMPARATOR | Placebo once daily in the morning for 27 ± 2 days |
| GW870086 1mg | EXPERIMENTAL | GW870086 1mg once daily in the morning for 27 ± 2 days |
| GW870086 3mg | EXPERIMENTAL | GW870086 3mg once daily in the morning for 27 ± 2 days |
| Name | Type | Description |
|---|---|---|
| GW870086 2mg | DRUG | oral inhalation |
| GW870086 4mg | DRUG | oral inhalation |
| GW870086 Placebo | DRUG | oral inhalation |
| GW870086 1mg | DRUG | oral inhalation |
| GW870086 3mg | DRUG | oral inhalation |
Inclusion Criteria: * Male or female between 18 and 65 years * A female subject is eligible to participate if she is of: Non-childbearing potential. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to discontinue HRT to allow confirmation of post...
GW870086 is an investigational small molecule being developed for the treatment of asthma. It is a respiratory therapeutic that has been studied in patients with asthma to evaluate its effect on lung function, specifically forced expiratory volume in 1 second (FEV1).
GW870086 is being developed by GSK plc, a global biopharmaceutical company. GSK plc is listed on the stock exchange under the ticker symbol GSK.
GW870086 is in Phase 2 clinical development. It has completed a Phase 2 clinical trial in patients with asthma, and it remains an investigational drug that has not been approved for commercial use.
GW870086 has been studied in one completed Phase 2 clinical trial, identified as NCT01245426. This trial evaluated the efficacy and dose response of repeat doses of GW870086X on forced expiratory volume in 1 second (FEV1) in asthmatics. The study enrolled 136 participants and was conducted in Bulgaria, Germany, and South Africa.
GW870086 is also known as GW870086X. The clinical trial NCT01245426 refers to the drug as GW870086X, indicating that these names refer to the same investigational compound.